The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 748K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

11 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region.EBI
Deciphera Pharmaceuticals
Discovery of acyl ureas as highly selective small molecule CSF1R kinase inhibitors.EBI
Deciphera Pharmaceuticals
Discovery of vimseltinib (DCC-3014), a highly selective CSF1R switch-control kinase inhibitor, in clinical development for the treatment of Tenosynovial Giant Cell Tumor (TGCT).EBI
Deciphera Pharmaceuticals
KV3 modulatorsBDB
Autifony Therapeutics
CDK Inhibitors And Their Use As PharmaceuticalsBDB
Prelude Therapeutics
INDAZOLE COMPOUNDS AS KINASE INHIBITORSBDB
Tyra Biosciences
Inhibitors for the B-catenin/B-cell lymphoma 9 (BCL9) protein-protein interactionBDB
H. Lee Moffitt Cancer Center and Research Institute
SUBSTITUTED PYRROLO-PYRIDINONE DERIVATIVES AND THERAPEUTIC USES THEREOFBDB
The Broad Institute
Granzyme B directed imaging and therapyBDB
Cytosite Biopharma
Monoamine oxidase inhibition by C4-substituted phthalonitriles.BDB
North-West University
A(3) adenosine receptors in human neutrophils and promyelocytic HL60 cells: a pharmacological and biochemical study.BDB
University of Ferrara